Autoimmune Diseases Therapies Market Size & Market Analysis

The global autoimmune disorder therapies market was valued at $53.2 billion in 2019. The market is expected to grow at a compound annual growth rate (CAGR) of 11.2% to reach $90.7 billion by 2024.

Autoimmune Diseases Therapies Market Size & Market Analysis

Growth of the global market is attributed to factors such as the growing prevalence of obesity, type 1 diabetes and other chronic diseases which leads to autoimmune diseases, a strong product regulatory scenario, and strong investment in research and development activities by key market players including AstraZeneca, Vertex Pharmaceuticals Incorporated, Bristol-Myers Squibb, F. Hoffmann-La Roche AG (Roche), Pfizer Inc., Amgen Inc., AbbVie Inc., Novartis, Johnson and Johnson, Mylan and Bayer.

Increase in incidence of autoimmune disease, surge in adoption of autoimmune disease therapeutics, and growth in R&D activities to develop ideal therapeutics are the key drivers of the global autoimmune disease therapeutics market. Furthermore, technological advancements in screening procedures, wide availability of therapeutics, and strong presence of pipeline drugs such as tocilizumab, baricitinib, certolizumab, secukinumab, etanercept, olokizumab, abatacept, apremilast, PF-06438179, golimumab, ustekinumab, etrolizumab, tofacitinib and others, are expected to further influence the market growth. On the other side, higher cost of advanced therapeutics can hamper the autoimmune disease therapeutics market growth.

Autoimmune Diseases Therapies Market Size & Market Analysis

The global autoimmune disease therapeutics market is segmented based on drug class, indication, sales channel, and region. Based on drug class, the market is classified as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. On the basis of indication rheumatic disease, type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and other indications. According to the sales channel, the market is categorized as hospital pharmacy, drug stores & retail pharmacy, and online store. Based on region, the autoimmune disease therapeutics market size is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, and rest of LAMEA).

Based on drug class, the market is classified as anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. Anti-inflammatory was the major revenue contributing segment in 2017 and is expected to exhibit dominance during the forecast period owing to increase in demand for anti- inflammatory drugs, launch of newer anti- inflammatory drugs with the supportive reimbursement policies for use of advanced anti- inflammatory drugs in some countries. Moreover, expected launch of pipeline anti-inflammatories such as tocilizumab, certolizumab, secukinumab, etanercept, golimumab and others, is estimated to further influence the market growth.

Anti-inflammatory drugs are preferably used in the treatment of inflammatory bowel disease, osteoarthritis, rheumatoid arthritis, fibromyalgia, systemic lupus erythematosus, gout, juvenile idiopathic arthritis, infectious arthritis, psoriatic arthritis, ankylosing spondylitis, reactive arthritis, scleroderma, polymyalgia rheumatica etc. Rise in incidence of these disease further fuels the market growth.

Presently, Adalimumab, Etanercept, Infliximab, Abatacept, Certolizumab, Golimumab, Ustekinumab, Tocilizumab, Secukinumab and others are widely used in the treatment of different form of autoimmune disease. Wide availability of anti-inflammatory drugs, preferable use of these drugs with favorable reimbursement in some countries contribute to the market growth.

Autoimmune Diseases Therapies Market Size & Market Analysis

Source :

Source :

Mid-Sized Businesses Have Low-Risk Options for Self-Funded Health Insurance

Running a mid-sized business is highly rewarding but also presents unique challenges. You don’t have a massive budget like major corporations, so providing health benefits to every employee can be difficult. If you’re ready to make a positive change without breaking your budget, read about how mid-sized businesses have low-risk options for self-funded health insurance.

What Is Self-Funded Health Insurance?

Individual plans for self-funded health insurance may vary, but they’re often more budget-friendly for business owners. Employers provide these plans and accept the financial risk of paying for healthcare expenses out of pocket. They set up trust funds for future claims so there’s always extra money readily available.

Third-party administrators (TPAs) will process the claims and handle the benefit plan. Employers only have to take ownership of each payment. If medical bills exceed the amount set aside in the trust fund, employers can utilize a stop-loss insurance plan to cover the remaining charges.

How Is Self-Funded Health Insurance Different?

Traditional insurance often costs more for small and mid-sized businesses. Employers agree to a specific plan with a locked-in premium. The premium covers the set number of enrolled employees and typically lasts for twelve months. If the business loses employees or the enrollees don’t use their full coverage, everyone still has to pay their monthly premium.

There’s also little to no risk for employers with traditional health insurance. The insurance company assumes total responsibility in covering claims outside of what’s required for enrollees to pay out-of-pocket.

Benefits of Providing Self-Funded Health Insurance

There are a few key benefits to providing self-funded health insurance as an employer or for enrolling as an employee. See if the following factors would make a difference in your financial and professional situation.

More Flexibility and Control

One health insurance plan doesn’t always cover everyone’s needs. People are different, so insurance options should provide flexibility. Self-funded insurance gives employers control over their terms so they can request what their team members specifically need. The TPA in charge of each client will customize the benefits according to the client’s budget.

Increased Financial Savings

There’s no such thing as pre-paying for self-funded plans or paying for insurance that people don’t use. Employers are also free from guaranteed renewal increases that would typically keep people locked into their plans.

If a business unexpectedly loses team members to competitors, self-funded insurance also allows for adjusted specifications. The price people pay when they begin their insurance plan doesn’t have to be what they pay after six months or a year of professional ups and downs.

Lower Monthly Premiums

Traditional insurance charges roughly $495 per month in the U.S., but self-funded insurance plans can charge much less. It may be a better arrangement for employers and team members who can’t afford a traditional arrangement that they may not use very often.

Look Into Your Low-Risk Options

Whether you’re an employer looking for a better financial solution to your health care options or someone seeking a budget-friendly monthly premium, learning about self-funded health insurance gives you more options. They’re low-risk arrangements that often work out well for small and mid-sized businesses, so see if it’s the best next step for your needs.

GoMeyra LIMS Expands Lab and Medical Practice Network as National Need for COVID-19 Testing Persists

GoMeyra LIMS Expands Lab and Medical Practice Network as National Need for COVID-19 Testing Persists

GoMeyra LIMS Expands Lab and Medical Practice Network as National Need for COVID-19 Testing Persists

Revolutionary new lab tech software system adds capabilities to allow for low-cost, large-scale PCR COVID-19 testing

LAS VEGAS–(BUSINESS WIRE)–#COVID19–More medical laboratories and practices across the country can now provide COVID-19 test results within hours, thanks to the revolutionary new tech solution, GoMeyra LIMS (laboratory information management system), which triples daily testing capacity.

The innovative cloud-based solution enables unprecedented COVID-19 processing times for PCR, rapid antigen and antibody testing, as well as vaccine monitoring. Serving as the end-to-end processing platform for dozens of U.S. labs and medical practices, GoMeyra LIMS is transforming the industry and boosting productivity at a time when the country needs a new level of efficiency in lab testing services more than ever.

GoMeyra LIMS works with organizations including labs, medical providers and contractors, enterprise-level corporations, universities, online casino, live entertainment productions and professional sporting events to handle large-scale testing, helping to control the coronavirus outbreak and get more Americans back to work, school, travel and normal activities.

“GoMeyra LIMS empowers us to be part of the solution for the nation’s testing problems. With the increased accessioning speed GoMeyra enables, we can process a lot more tests – which in turn lowers the price,” said Sam Zhang, CEO at American Molecular Laboratories. “This increased efficiency allows us to offer the most competitive bulk rates for organizations, universities and school districts across the country, which can now afford the large-scale testing needed to get people back to work and students back in classrooms.”

A Silicon Valley visionary and experienced systems IT developer created GoMeyra during the COVID-19 lockdown to address the testing crisis created by the pandemic, which exposed the drawbacks of antiquated systems and workforce shortages at labs across the country. Founder and Chief Executive Officer Jaswant S. Tony saw how great the need for increased laboratory efficiencies was and tapped proven expertise to solve the problem.

“GoMeyra is increasingly positioned to usher laboratories into a new era of adaptability and efficiency through advanced automation features that enable medical labs to process more tests with fewer resources in record time,” said Tony. “With the addition of new labs and medical practice clients, GoMeyra continues to expand its network and make faster testing accessible to more people.”

A sampling of new laboratory and medical practice clients now powered by GoMeyra LIMS include: University of South Carolina in Columbia, SC, handling on-campus rapid testing; COVID Testing LLC in Orlando, managing student testing for the University of Central Florida; American Molecular Laboratories in Chicago; Millenia Advanced Scientific in Orlando, Vital Medical Diagnostics Inc. in Houston; and Vitae Diagnostics in Southern California.

These new clients join a long list of other medical providers that were among the first organizations to benefit from GoMeyra LIMS’ innovative software, including laboratories Atlas Genomics in Seattle, Austin, Atlanta, Boston and Los Angeles; BalboaDx in Southern California; and Athlete Advantage Medical, a medical practice handling closed-circuit COVID and medical testing for athletes and staff of televised professional fights promoted by UFC, Top Rank, Golden Boy and Bellator, as well as competition events such as Miss USA, Miss Teen USA and the World’s Strongest Man.

About GoMeyra LIMS

GoMeyra LIMS is a comprehensive, fully customizable, cloud-based laboratory information management system that can be onboarded with unprecedented speed, in as little as two days. World-class scientists, lab informatics, enterprise-level software engineers and technology architects tapped decades of experience in designing GoMeyra with proprietary capabilities that help laboratories easily operate with as much automation, contact-free processes and regulatory compliance as possible.

GoMeyra LIMS alleviates bottlenecks and increases efficiency challenges inherent in laboratory workflows. The system comprises innovative features such as the employer-facing GoMeyra SCAN app – a customized portal that allows administrators to scan an employee’s or a student’s QR code or badge to validate test results and vaccinations, and authorize returns to work or school; a connected lab-to-lab network for overflow testing, reference specimens and correlation; front-end LIMS integration with client electronic medical records (EMR); digital scanning for monitoring and recording the journey of each specimen in real-time; flexible batch scalability that coordinates instrumentation with sample volume and labs that conduct pooled testing; built-in inventory management; and much more.

For more information, visit or follow @gomeyra on Facebook, Twitter, LinkedIn, Instagram or YouTube. For a demonstration of GoMeyra LIMS, contact or call (844) 203-3960.


Media Contacts:
Gina Yager, Mindy Eras

GYC Vegas

(702) 560-6590

Enzyme essential to malaria replication could be a target for future treatments

Source : Enzyme essential to malaria replication could be a target for future treatments (

Researchers at the Francis Crick Institute have identified an enzyme vital to the survival of the malaria parasite. The work could lead to the development of a new class of antimalarial treatments which target this enzyme and stop the parasite replicating in the blood.

The malaria parasite has a complex life-cycle which includes invading red blood cells in order to replicate. As the parasites multiply within a cell, they eventually cause it to burst and the new parasites are released back into the blood stream where they enter other cells and the process repeats.

In their study, published in eLife, the researchers identified how the malaria parasite Plasmodium falciparum needs an enzyme, called SUB2, to successfully enter and survive in red blood cells.

Read the full article – Read More

Alzheimer’s Disease Pathway Identified as Potential Early Therapeutic Target

Source : Alzheimer’s Disease Pathway Identified as Potential Early Therapeutic Target (

Researchers at Case Western Reserve University School of Medicine have identified a molecular pathway in Alzheimer’s disease (AD) that could lead to the development of new therapeutic approaches to target the neurodegenerative condition early in its progression. The team’s studies, in cells from human AD patients and in mouse models of the disease, indicated that the pathway, known as Drp1-HK1-NLRP3, plays a key role in disrupting the normal function of brain cells that produce the protective white matter myelin sheath that wraps around neurons.

“This is a missing part of the puzzle,” said research lead Xin Qi, PhD, a professor in the department of physiology and biophysics at the School of Medicine. “We’ve discovered a pathway that is accessible to detection and potential treatment, prior to much of the disease’s damage and well before clinical symptoms appear.” Reporting on their findings in Science Advances (“Oligodendroglial glycolytic stress triggers inflammasome activation and neuropathology in Alzheimer’s disease,”) Qi and colleagues concluded, “Overall, our findings provide previously unidentified insights into the mechanism of white matter degeneration in AD and thus identify a new area for potential therapeutic intervention … The Drp1-HK1-NLRP3 signaling axis may be a key mechanism and therapeutic target for white matter degeneration in AD.”

Read the full article – Read More

Nanobody approach prevents the destruction of imperfect but still perfectly functional proteins

Source : Synthetic llama antibodies rescue doomed proteins inside cells — ScienceDaily

Columbia researchers have created a new technology using synthetic llama antibodies to prevent specific proteins from being destroyed inside cells. The approach could be used to treat dozens of diseases, including cystic fibrosis, that arise from the destruction of imperfect but still perfectly functional proteins.

In many genetic diseases, including cystic fibrosis, mutated proteins are capable of performing their jobs but are tagged for destruction by the cell’s quality control mechanisms.

In the cell, proteins destined for destruction are marked with a small peptide called ubiquitin. Deubiquitinase enzymes (DUBs) can remove these tags, but simply increasing DUB activity would indiscriminately rescue all proteins in a cell marked for destruction, which would be harmful.

Read the full article – Read More

For the first time, researchers describe how Rho protein really stops gene expression

Source : Biology Textbooks Wrong? New Research Reveals the Secret Behind a Key Cellular Process (

New research has identified and described a cellular process that, despite what textbooks say, has remained elusive to scientists until now — precisely how the copying of genetic material that, once started, is properly turned off.

The finding concerns a key process essential to life: the transcription phase of gene expression, which enables cells to live and do their jobs.

During transcription, an enzyme called RNA polymerase wraps itself around the double helix of DNA, using one strand to match nucleotides to make a copy of genetic material — resulting in a newly synthesized strand of RNA that breaks off when transcription is complete. That RNA enables production of proteins, which are essential to all life and perform most of the work inside cells.

Just as with any coherent message, RNA needs to start and stop in the right place to make sense. A bacterial protein called Rho was discovered more than 50 years ago because of its ability to stop, or terminate, transcription. In every textbook, Rho is used as a model terminator that, using its very strong motor force, binds to the RNA and pulls it out of RNA polymerase. But a closer look by these scientists showed that Rho wouldn’t be able to find the RNAs it needs to release using the textbook mechanism.

Read the full article – Read More

DeepMind develops AI solution to Solve Big Challenge of Protein Structure Prediction

Source : Major Scientific Advance: DeepMind AI AlphaFold Solves 50-Year-Old Grand Challenge of Protein Structure Prediction (

In a major scientific advance, the latest version of DeepMind’s AI system AlphaFold has been recognized as a solution to the 50-year-old grand challenge of protein structure prediction, often referred to as the ‘protein folding problem’, according to a rigorous independent assessment. This breakthrough could significantly accelerate biological research over the long term, unlocking new possibilities in disease understanding and drug discovery among other fields.

Today, results from CASP14 show that DeepMind’s latest AlphaFold system achieves unparalleled levels of accuracy in structure prediction. The system is able to determine highly-accurate structures in a matter of days. CASP, the Critical Assessment of protein Structure Prediction, is a biennial community-run assessment started in 1994, and the gold standard for assessing predictive techniques. Participants must blindly predict the structure of proteins that have only recently — or in some cases not yet — been experimentally determined, and wait for their predictions to be compared to experimental data.

Read the full article – Read More

New Lab-on-a-Chip Could Enable Fast, Easy Testing for Colds, Flu, UTIs, and COVID-19 at Home

Source : New Lab-on-a-Chip Could Enable Fast, Easy Testing for Colds, Flu, UTIs, and COVID-19 at Home (

The chip, developed at Imperial College London and known as TriSilix, is a ‘micro laboratory’ which performs a miniature version of the polymerase chain reaction (PCR) on the spot. PCR is the gold-standard test for detecting viruses and bacteria in biological samples such as bodily fluids, feces, or environmental samples.

Although PCR is usually performed in a laboratory, which means test results aren’t immediately available, this new lab-on-a-chip can process and present results in a matter of minutes.

The chip is made from silicon, the same material that is used to make electronic chips. Silicon itself is cheap, however, it is expensive to process into chips which requires massive, ‘extremely clean’ factories otherwise known as cleanrooms. To make the new lab-on-chip, the researchers developed a series of methods to produce the chips in a standard laboratory, cutting the costs and time they take to fabricate, potentially allowing them to be produced anywhere in the world.

Read the full article – Read More